EGFR-AS1 Promotes Bladder Cancer Progression by Upregulating EGFR

被引：19

作者：

Wang, Anbang ^{[1
]}

Jiang, Aimin ^{[1
]}

Gan, Xinxin ^{[1
]}

Wang, Zheng ^{[1
]}

Huang, Jinming ^{[1
]}

Dong, Kai ^{[1
]}

Liu, Bing ^{[1
]}

Wang, Linhui ^{[1
]}

Chen, Ming ^{[1
]}

机构：

[1] Naval Med Univ, Changzheng Hosp, Dept Urol, Shanghai 200003, Peoples R China

来源：

BIOMED RESEARCH INTERNATIONAL | 2020年 / 2020卷

基金：

中国国家自然科学基金;

关键词：

METASTATIC UROTHELIAL CARCINOMA; LONG NONCODING RNA; GROWTH;

D O I：

10.1155/2020/6665974

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Long noncoding RNAs play an essential role in bladder cancer progression. The role of long noncoding RNA EGFR-AS1 in bladder cancer needs further study. We used clinical specimens to analyze the relationship between EGFR-AS1 and bladder cancer patients' characteristics. The functional experiments and mechanism studies were performed using qRT-PCR, transwell assay, survival analysis, and correlation analysis. We found that high expression of EGFR-AS1 was nearly related to aggressive bladder cancer and indicated poor prognosis for patients. The functional experiments in vivo and in vitro suggested that EGFR-AS1 promoted the proliferation and invasion of bladder cancer cells. Mechanically, EGFR-AS1 promoted the expression of EGFR by inhibiting the degradation of EGFR mRNA, thereby promoting the metastasis of bladder cancer. In addition, EGFR-AS1/EGFR may be involved in the immune-related pathways of bladder cancer. These studies indicate that the EGFR-AS1/EGFR pathway may be a potential diagnostic marker and therapeutic target for bladder cancer.

引用

页数：9

共 15 条

[1] Management of muscle invasive, locally advanced and metastatic urothelial carcinoma of the bladder: a literature review with emphasis on the role of surgery [J].

Abufaraj, Mohammad ;

Gust, Kilian ;

Moschini, Marco ;

Foerster, Beat ;

Soria, Francesco ;

Mathieu, Romain ;

Shariat, Shahrokh F. .

TRANSLATIONAL ANDROLOGY AND UROLOGY, 2016, 5 (05) :735-744

[2] Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations [J].

Choudhury, Noura J. ;

Campanile, Alexa ;

Antic, Tatjana ;

Yap, Kai Lee ;

Fitzpatrick, Carrie A. ;

Wade, James L., III ;

Karrison, Theodore ;

Stadler, Walter M. ;

Nakamura, Yusuke ;

O'Donnell, Peter H. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18) :2165-+

[3] A DDX31/Mutant-p53/EGFR Axis Promotes Multistep Progression of Muscle-Invasive Bladder Cancer [J].

Daizumoto, Kei ;

Yoshimaru, Tetsuro ;

Matsushita, Yosuke ;

Fukawa, Tomoya ;

Uehara, Hisanori ;

Ono, Masaya ;

Komatsu, Masato ;

Kanayama, Hiro-omi ;

Katagiri, Toyomasa .

CANCER RESEARCH, 2018, 78 (09) :2233-2247

[4] The lncRNA EGFR-AS1 is linked to migration, invasion and apoptosis in glioma cells by targeting miR-133b/RACK1 [J].

Dong, Zhi-Qiang ;

Guo, Zhao-Yu ;

Xie, Jun .

BIOMEDICINE & PHARMACOTHERAPY, 2019, 118

[5] Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway [J].

Gao, Yanjun ;

Liu, Shanhui ;

Guo, Qi ;

Zhang, Su ;

Zhao, Youli ;

Wang, Hanzhang ;

Li, Tianbao ;

Gong, Yuwen ;

Wang, Yuhan ;

Zhang, Tao ;

Dong, Zhilong ;

Bacich, Dean ;

Chowdhury, Wasim H. ;

Rodriguez, Ronald ;

Wang, Zhiping .

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2019, 15 (07) :1488-1499

[6] S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy [J].

Kim, W. T. ;

Kim, J. ;

Yan, C. ;

Jeong, P. ;

Choi, S. Y. ;

Lee, O. J. ;

Chae, Y. B. ;

Yun, S. J. ;

Lee, S. C. ;

Kim, W. J. .

ANNALS OF ONCOLOGY, 2014, 25 (05) :974-979

[7] Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk [J].

Peng, Mei ;

Huang, Yanjun ;

Tao, Ting ;

Peng, Cai-Yun ;

Su, Qiongli ;

Xu, Wanjun ;

Darko, Kwame Oteng ;

Tao, Xiaojun ;

Yang, Xiaoping .

SCIENTIFIC REPORTS, 2016, 6

[8] Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial [J].

Powles, Thomas ;

Duran, Ignacio ;

van der Heijden, Michiel S. ;

Loriot, Yohann ;

Vogelzang, Nicholas J. ;

De Giorgi, Ugo ;

Oudard, Stephane ;

Retz, Margitta M. ;

Castellano, Daniel ;

Bamias, Aristotelis ;

Flechon, Aude ;

Gravis, Gwenaelle ;

Hussain, Syed ;

Takano, Toshimi ;

Leng, Ning ;

Kadel, Edward E., III ;

Banchereau, Romain ;

Hegde, Priti S. ;

Mariathasan, Sanjeev ;

Cui, Na ;

Shen, Xiaodong ;

Derleth, Christina L. ;

Green, Marjorie C. ;

Ravaud, Alain .

LANCET, 2018, 391 (10122) :748-757

[9] A phase 3 study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC) chemotherapy (CT) in patients (pts) with unresectable Stage IV urothelial bladder cancer (UBC): DANUBE [J].

Powles, Thomas ;

Galsky, Matt D. ;

Castellano, Daniel ;

Van Der Heijden, Michiel Simon ;

Petrylak, Daniel Peter ;

Armstrong, Jon ;

Belli, Riccardo ;

Ferro, Salvatore ;

Ben, Yong ;

Bellmunt, Joaquim .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[10] Long Noncoding RNAs in Cancer Pathways [J].

Schmitt, Adam M. ;

Chang, Howard Y. .

CANCER CELL, 2016, 29 (04) :452-463

← 1 2 →